Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, although a clinical trial using the anti-IL-6 receptor antibody tocilizumab is underway, it is important to recognize the state of SSc patients prior to selecting treatment.
|
30561237 |
2019 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The objective of the study was to investigate how serum levels of YKL-40 and IL-6 correlate with articular and periarticular involvement in patients with SSc assessed by high-frequency ultrasonography.
|
31375891 |
2019 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tocilizumab is an IL-6 receptor antagonist established as safe and effective, primarily in rheumatoid arthritis, and has shown promise in scleroderma.
|
28956500 |
2019 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of IL-6 were significantly elevated in SSc patients (p = 0.024) and were positively correlated with the modified Rodnan skin score (rs = 0.291, p =0.041).
|
31397760 |
2019 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that vasculopathy-induced hypoxia and oxidative stress might enhance ATP release in the dermis in SSc and that extracellular ATP-induced phosphorylation of p38 via P2Y<sub>2</sub> receptor might enhance IL-6 and collagen type I production in SSc fibroblasts.
|
30404019 |
2019 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results highlight the importance of IL-6 as a key mediator in the altered cytokine network of SSc.
|
30652681 |
2019 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, an increase of IL-1β and IL-6 serum levels in SSc patients was found as well as a positive correlation between MIF serum levels and Th1 and Th17 cytokine profiles.
|
30747392 |
2019 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to the profibrotic role of interleukin 6 and transforming growth factor-β, newer studies stress on glycoprotein Krebs von den Lungen-6 (KL-6), surfactant protein-D (SP-D) and chemokine (C-C motif) ligand 18 (CCL18) as potential biomarkers of skin and lung fibrosis in SSc.<b>Expert opinion</b>: Skin and lung biomarkers in SSc frequently mirror the typical signs of fibrosis, overlapping sporadically.
|
31539483 |
2019 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Classical targets for fibrosis in SSc like transforming growth factor Beta (TGF-β), Interleukin-6 (IL-6), and multiple tyrosine kinases, have not yielded therapeutic benefit.
|
31073660 |
2019 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In dcSSc fibroblasts, stimulation with SSc-ICs and NHS-ICs upregulated IL-6 and IL-8.
|
30157947 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
After stimulation, we observed a lower proportion of IL-10 and IL-6 producing B-cells in SSc.
|
29343447 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases.
|
29853453 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In unstimulated PBMC, the production of TNF(p = 0.004), IL-10(p = .048), IL-2(p < 0.001), and IL-6 (p = 0.01) was higher in SSc patients than in healthy controls.
|
29601941 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A bleomycin-induced scleroderma model was induced in mice with a B cell-specific deficiency in IL-6 or IL-10.
|
30009261 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was evidence of altered distribution of transitional B cell subsets, increased production of interleukin-6 (IL-6) and IL-8, and defective tolerance induction in SSc B cells.
|
29193892 |
2018 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression level of IL-6 gene was significantly higher in patients with SSc in comparison with healthy controls (p < 0.05).
|
29948346 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The comparative secretion of IL-6 by SSc-MDMs and SSc-AM is concordant with these phenotypic considerations.
|
29562615 |
2018 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, the rapid decrease in serum IL-6 levels during a couple of doses may predict the efficacy of IVCY therapy against SSc-ILD.
|
30051925 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-17A or TGF-β enhanced the production of IL-6 by 8- to 16-folds when compared to control in healthy donors (HD) and SSc cultures.
|
30150989 |
2018 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the role of cytokine (interleukin-1β, interleukin-6) and connective tissue growth factor (CTGF) production, and extracellular signal-regulated kinases (ERK) activation in mediating P2X7R-dependent pro-fibrotic effects in SSc fibroblasts was evaluated.
|
28955239 |
2017 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum levels of IL-1β, IL-12 and IL-6 in PSS patients were significantly lower than those in controls (P < 0.003), and these associations survived the Bonferroni correction (Pc < 0.018).
|
28384257 |
2017 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A possible role of IL-6 in the regulation of firoblast differentiation and stimulation of collagen synthesis has been suggested and in patients with systemic sclerosis (SSc) the treatment with tocilizumab (TCZ) was associated to improvement of skin thickness and joint motion.
|
28980909 |
2017 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the levels of IL-6 (mean ± SD 314.3 ± 317.8 pg/ml versus 6.10 ± 2.58 pg/ml; P = 0.0007) and TGFβ (mean ± SD 1,020 ± 569 pg/ml versus 163.8 ± 98.69 pg/ml; P = 0.001) secreted by B lymphocytes from patients with SSc were increased compared to healthy controls.
|
27992693 |
2017 |
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of CCL2, IL-10, and IL-6 were measured in 171 patients with early SSc in the Canadian Scleroderma Research Group (CSRG) replication cohort.
|
28575534 |
2017 |
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fraction exhaled nitric oxide (FeNO) and exhaled carbon monoxide (eCO) measured in EB, together with pH, nitrite, nitrate and interleukin-6 levels measured in EBC were prospectively analyzed in 35 patients with SSc.
|
28038794 |
2017 |